Sarclisa recommended for EU approval by the CHMP to treat transplant-ineligible newly diagnosed multiple myeloma Recommendation based on IMROZ phase 3 study demonstrating Sarclisa in ...

Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria Resubmission includes new pivotal data which confirm Dupixent significantly reduced itch and ...

Dupixent approved in the EU as the first and only medicine for young children with eosinophilic esophagitis Approval based on phase 3 data showing significantly more children aged one to 11 ...

Although presymptomatic T1D (Stages 1 and 2) can be detected months or years before symptoms appear, most people are not diagnosed until they feel unwel. 10 11 Over the past 50 years, scientists ...

In the annual diversity, equity and inclusion (DE&I) Report, Sanofi takes stock of progress on the three pillars of the DE&I strategy. On the ‘building representative leadership’ pillar: 45%1 of ...

In many countries, minimum wages are insufficient to guarantee that workers and their families can meet basic needs. Sanofi is proud to go beyond the minimum by committing to a living wage for all ...

Since January 1, 2024, the program's flagship measure - 12 months' salary, social protection and employment guarantee - has been in place for all employees affected by cancer, regardless of their ...

A booster to transform breakthrough technologies and processes developed by best-in-class academic partners and start-ups into innovative solutions to accelerate our R&D portfolio. In 2022, the ...

Sanofi has a hybrid workplace where employees decide how they want to work. We realise the value of diversity and offer a range of benefits for the health of our employees and their families We work ...

Janvier 2022 a marqué un tournant dans la prise en charge du diabète de Type 1. Après plus d’un siècle de traitements à base d’insuline, patients et médecins ont désormais une nouvelle option : la ...

Dans le rapport annuel sur la Diversité, Équité et Inclusion, Sanofi fait le point sur les progrès dans les trois piliers de la stratégie DE&I. Note de 8,1 sur 10 à l’index DE&I à la dernière enquête ...

Before becoming a sepsis survivor, Kim was a busy woman, running multiple businesses. But a urinary tract infection she contracted on holiday quickly progressed into sepsis. Nine weeks later, she ...